TARS
NASDAQTarsus Pharmaceuticals Inc.
News · 26 weeks86+200%
2026-03-012026-08-23
Mix3890d
- Insider17(45%)
- SEC Filings11(29%)
- Earnings4(11%)
- Other3(8%)
- Offering2(5%)
- Leadership1(3%)
Latest news
25 items- SECSEC Form 144 filed by Tarsus Pharmaceuticals Inc.144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- PRAlkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt DiseaseCAMBRIDGE, Mass., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted Orphan Drug Designation for oral gildeuretinol for the treatment of Stargardt disease. Stargardt disease is an inherited retinal disease that often begins in childhood or adolescence, and progressively and irreversibly damages the central vision patients rely on to read, recognize faces, drive and live independently. Gildeuretinol currently is being evaluated in the global Phase 3 NORTHSTAR Study. "Receiving orph
- SECSEC Form 144 filed by Tarsus Pharmaceuticals Inc.144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tarsus Pharmaceuticals Inc.SCHEDULE 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- SECSEC Form 10-Q filed by Tarsus Pharmaceuticals Inc.10-Q - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
- SECTarsus Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
- SECTarsus Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
- SECTarsus Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
- PRTarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of GrowthGenerated second quarter 2026 XDEMVY® net product sales of $173.9 million, an increase of more than 69% year-over-year Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million Pending acquisition of Alkeus Pharmaceuticals to expand Tarsus’ retina pipeline with a Phase 3 clinical program for Stargardt disease, an inherited retinal disease affecting more than 36,000 patients in the United States that can lead to blindness Priced $125 million private placement financing which included participation from top-tier funds and several existing Alkeus Pharmaceuticals investors Management to host conference call today, August 6, 2026, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE,
- PRTarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity FinancingIRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) ("Tarsus") today announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $125.0 million, before deducting placement agent fees and other private placement expenses. The PIPE financing includes participation from existing investors of Alkeus Pharmaceuticals ("Alkeus"), including TCGX, Bain Capital Life Sciences, and Wellington Management. Tarsus announced the pending acquisition of Alkeus in a press
- PRTarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership PositionAdds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of the largest inherited retinal diseases with no FDA-approved therapy 400+ individuals treated to date, with encouraging positive structural and functional clinical findings; and over seven years of long-term tolerability data Top-line Phase 3 NORTHSTAR data expected in the second half of 2029; Has received Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations Together with IRX-101, this acquisition is expected to expand Tarsus’ presence in retina and further strengthen one of
- PRTarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026IRVINE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Thursday, August 6, 2026 to report its second quarter 2026 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to
- SECTarsus Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
- PRTarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of GrowthIRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new opportunity as Chief Executive Officer of a public medical device company. Effective immediately, Neera Clase, formerly Senior Vice President of Market Access, will serve as Interim Chief Commercial Officer while Tarsus conducts a search for a permanent successor. Since joining Tarsus in 2021, Ms. Clase has played an integral role in the Company's evolution from a clinical-stage organization to a successful commercial biopharmaceutical company with one of the best launches in eye care to date. H
- SECTarsus Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
- PRTarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care Positive Phase 2b/3 data and an FDA-aligned Phase 3 program provide a clear and near-term path forward; transaction structured to align economics with future value creation Tarsus to host investor conference call today, July 8, 2026, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced the acquisition of iRenix Medical, Inc., a privately held, clinical-stage ophthalmic biopharmaceutical company and developer of IRX-101, an investigational ocular antiseptic with the poten
- INSIDERSEC Form 4 filed by Director Chaudhuri Bhaskar4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Director Morrison Scott W4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Director Goldberg Andrew D.4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Director Goodrich Katherine4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Director Yarno Wendy L4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Director Pyott David E I4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Director Link William J Phd4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SECTarsus Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
- INSIDERPresident/CEO and Board Chair Azamian Bobak R. sold $615,488 worth of shares (10,000 units at $61.55) as part of a pre-agreed trading plan (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
TARS FAQ
7 questionsWhat does Tarsus Pharmaceuticals Inc. do?
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in...Where does TARS stock trade?
Tarsus Pharmaceuticals Inc. (TARS) is listed on NASDAQ.What sector and industry is TARS in?
Tarsus Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Tarsus Pharmaceuticals Inc. go public?
Tarsus Pharmaceuticals Inc. (TARS) completed its IPO in 2020.What are analysts saying about TARS?
Tarsus Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform on 2026-04-24. Recent price targets range from $1900.00 to $4400.00.What companies are similar to TARS?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare TARS side-by-side with any of them on Quantisnow.How can I track TARS on Quantisnow?
Quantisnow aggregates Tarsus Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TARS to receive live email and push alerts on every new disclosure.